Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods.
Lipids comprise the bulk of the dry mass of the brain. In addition to providing structural integrity to membranes, insulation to cells and acting as a source of energy, lipids can be rapidly converted to mediators of inflammation or to signaling molecules that control molecular and cellular events in the brain. The advent of soft ionization procedures such as electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) have made it possible for compositional studies of the diverse lipid structures that are present in brain. These include phospholipids, ceramides, sphingomyelin, cerebrosides, cholesterol and their oxidized derivatives. Lipid analyses have delineated metabolic defects in disease conditions including mental retardation, Parkinson's Disease (PD), schizophrenia, Alzheimer's Disease (AD), depression, brain development, and ischemic stroke. In this review, we examine the structure of the major lipid classes in the brain, describe methods used for their characterization, and evaluate their role in neurological diseases. The potential utility of characterizing lipid markers in the brain, with specific emphasis on disease mechanisms, will be discussed. Additionally, we describe several proteomic strategies for characterizing lipid-metabolizing proteins in human cerebrospinal fluid (CSF). These proteins may be potential therapeutic targets since they transport lipids required for neuronal growth or convert lipids into molecules that control brain physiology. Combining lipidomics and proteomics will enhance existing knowledge of disease pathology and increase the likelihood of discovering specific markers and biochemical mechanisms of brain diseases.
Fonteh
Alfred N
AN
Molecular Neurology Program, Huntington Medical Research Institutes, Pasadena, CA 91101, USA. afonteh@hmri.org
Harrington
Robert J
RJ
Huhmer
Andreas F
AF
Biringer
Roger G
RG
Riggins
James N
JN
Harrington
Michael G
MG
D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000134:cerebrospinal fluid*; D001523:Mental Disorders / Q000175:diagnosis* / Q000378:metabolism; D009422:Nervous System Diseases / Q000175:diagnosis* / Q000378:metabolism; D040901:Proteomics / Q000379:methods*
D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D008055:Lipids